These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33774921)

  • 1. Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitor.
    Khialani D; Vasan S; Cushman M; Dahm AEA; Sandset PM; Rossouw J; van Hylckama Vlieg A
    J Thromb Haemost; 2021 Jul; 19(7):1729-1737. PubMed ID: 33774921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy.
    Roach RE; Lijfering WM; Helmerhorst FM; Cannegieter SC; Rosendaal FR; van Hylckama Vlieg A
    J Thromb Haemost; 2013 Jan; 11(1):124-31. PubMed ID: 23136837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between sex hormone binding globulin and blood coagulation in women on postmenopausal hormone treatment.
    Eilertsen AL; Dahm AEA; Høibraaten E; Lofthus CM; Mowinckel MC; Sandset PM
    Blood Coagul Fibrinolysis; 2019 Jan; 30(1):17-23. PubMed ID: 30507711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI.
    Raps M; Helmerhorst FM; Fleischer K; Dahm AE; Rosendaal FR; Rosing J; Reitsma P; Sandset PM; van Vliet HA
    Thromb Haemost; 2013 Apr; 109(4):606-13. PubMed ID: 23407778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.
    Johnson KC; Aragaki AK; Jackson R; Reiner A; Sandset PM; Rosing J; Dahm AE; Rosendaal F; Manson JE; Martin LW; Liu S; Kuller LH; Cushman M; Rossouw JE
    Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):418-24. PubMed ID: 26681757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy.
    Rossouw JE; Johnson KC; Pettinger M; Cushman M; Sandset PM; Kuller L; Rosendaal F; Rosing J; Wasserthal-Smoller S; Martin LW; Manson JE; Lakshminarayan K; Merino JG; Lynch J
    Stroke; 2012 Apr; 43(4):952-7. PubMed ID: 22363056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
    Post MS; Christella M; Thomassen LG; van der Mooren MJ; van Baal WM; Rosing J; Kenemans P; Stehouwer CD
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1116-21. PubMed ID: 12730085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregnancy-associated changes in the hemostatic system in wild-type and factor V Leiden mice.
    Tchaikovski SN; van Vlijmen BJ; Cleuren AC; Thomassen MC; Tchaikovski V; Tans G; Rosing J
    J Thromb Haemost; 2009 Feb; 7(2):312-8. PubMed ID: 19036061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Serum Sex Hormones with Hemostatic Factors in Women On and Off Hormone Therapy: The Multiethnic Study of Atherosclerosis.
    Williams MS; Cushman M; Ouyang P; Heckbert SR; Kalyani RR; Vaidya D
    J Womens Health (Larchmt); 2016 Feb; 25(2):166-72. PubMed ID: 26700933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and stroke.
    Duering C; Kosch A; Langer C; Thedieck S; Nowak-Göttl U
    Thromb Haemost; 2004 Oct; 92(4):707-12. PubMed ID: 15467899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of tissue factor pathway inhibitor in hormone-induced venous thromboembolism.
    Arafat A; Gennari P; Ignatov A; Tchaikovski S
    Blood Coagul Fibrinolysis; 2023 Jun; 34(4):233-238. PubMed ID: 37115963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy.
    Opstad TB; Eilertsen AL; Høibraaten E; Skretting G; Sandset PM
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):516-21. PubMed ID: 20453636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasma.
    Alshaikh NA; Rosing J; Thomassen MCLGD; Castoldi E; Simioni P; Hackeng TM
    J Thromb Haemost; 2017 May; 15(5):950-960. PubMed ID: 28211163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thrombosis and conjugated equine estrogen in women without a uterus.
    Curb JD; Prentice RL; Bray PF; Langer RD; Van Horn L; Barnabei VM; Bloch MJ; Cyr MG; Gass M; Lepine L; Rodabough RJ; Sidney S; Uwaifo GI; Rosendaal FR
    Arch Intern Med; 2006 Apr; 166(7):772-80. PubMed ID: 16606815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism.
    Bergrem A; Dahm AE; Jacobsen AF; Mowinckel MC; Sandvik L; Sandset PM
    Br J Haematol; 2011 Jul; 154(2):241-7. PubMed ID: 21564075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers, menopausal hormone therapy and risk of venous thrombosis: The Women's Health Initiative.
    Cushman M; Larson JC; Rosendaal FR; Heckbert SR; Curb JD; Phillips LS; Baird AE; Eaton CB; Stafford RS
    Res Pract Thromb Haemost; 2018 Apr; 2(2):310-319. PubMed ID: 30046733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial.
    Høibraaten E; Mowinckel MC; de Ronde H; Bertina RM; Sandset PM
    Br J Haematol; 2001 Nov; 115(2):415-20. PubMed ID: 11703344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of thrombosis related to hormone therapy.
    Sandset PM; Høibraaten E; Eilertsen AL; Dahm A
    Thromb Res; 2009; 123 Suppl 2():S70-3. PubMed ID: 19217481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
    Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
    Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total tissue factor pathway inhibitor and venous thrombosis. The Longitudinal Investigation of Thromboembolism Etiology.
    Zakai NA; Lutsey PL; Folsom AR; Heckbert SR; Cushman M
    Thromb Haemost; 2010 Aug; 104(2):207-12. PubMed ID: 20431849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.